Baxter BioScience acquires Oncaspar portfolio for leukaemia for $900m
Baxter has signed a definitive agreement to acquire the Oncaspar® (pegaspargase) product portfolio from Sigma-Tau for US $900 million.
List view / Grid view
News
Highland Therapeutics to present clinical data on its ADHD treatment at APA 2015
12 May 2015 | By Victoria White
Highland Therapeutics has announced that it will host a poster presentation highlighting Phase III clinical data for its ADHD treatment at APA 2015...
Muscular Dystrophy treatment pipeline offers hope for improved life expectancy, says GBI Research
12 May 2015 | By Victoria White
GBI Research reports on the highly diverse and innovative pipeline for Duchenne Muscular Dystrophy and Becker Muscular Dystrophy treatment...
Seven partners “Hear” pharmaceutical lifecycle challenges together
12 May 2015 | By Klyo Collaborative
Seven companies have voluntarily come together to form a new collaborative problem-solving group, aimed at assisting biopharmaceutical companies solve their most pressing lifecycle pipeline problems...
FDA Fast Track designation for evofosfamide for treatment of patients living with advanced pancreatic cancer
12 May 2015 | By Victoria White
The FDA has granted Fast Track designation for the development of evofosfamide for the treatment of patients with advanced pancreatic cancer...
Penn Pharma a PCI company, installs new Gerteis Roller Compactor Technology
12 May 2015 | By Penn Pharma
Pharmaceutical manufacturer Penn Pharma a PCI company, today announced the successful installation of the Gerteis Mini-Pactor at its contained manufacturing facility...
CPhI Istanbul 2015 opens as Turkey continues to dominate the MENA pharma region
12 May 2015 | By Victoria White
CPhI Istanbul (#cphiIstanbul), organised by UBM EMEA, will return to ICC Istanbul Congress Center, Istanbul, Turkey from 3 to 5 June 2015...
Inovio initiates Phase I trial of its Ebola DNA immunotherapy
12 May 2015 | By Victoria White
Inovio Pharmaceuticals has initiated a Phase I trial to evaluate safety, tolerability and immune responses of its Ebola DNA immunotherapy...
First patient enrolled in Phase 3 study of ixazomib as maintenance therapy for newly diagnosed multiple myeloma
12 May 2015 | By Victoria White
Takeda has announced that the first patient has been enrolled in the Phase 3 TOURMALINE-MM4 study of investigational oral ixazomib...
Stroke rates have dramatically increased over the past 15 years
12 May 2015 | By Victoria White
The number of strokes occurring in men aged between 40 and 54 has rocketed by almost 50% in less than 15 years, according to the Stroke Association...
GW commences Phase 3 trial of Epidiolex for the treatment of Lennox-Gastaut syndrome
12 May 2015 | By Victoria White
GW Pharmaceuticals has commenced a Phase 3 clinical trial of Epidiolex (cannabidiol or CBD) for the treatment of Lennox-Gastaut syndrome (LGS)...
Pfizer acquires minority interest in AM-Pharma and secures option to acquire company
12 May 2015 | By Victoria White
Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company...
New data demonstrates Saxenda® (liraglutide 3 mg) provides benefits beyond weight loss
11 May 2015 | By Victoria White
Data from a post-hoc analysis of a Phase 3a trial demonstrates the weight-loss-dependent and independent effects of liraglutide 3 mg...
SMC accepts seven new medicines for use in NHS Scotland
11 May 2015 | By Victoria White
SMC has accepted seven new medicines for use in NHS Scotland. Two of these medicines, Azerra and Zydelig, were considered under SMC’s PACE process...
Boyds join clinical programme team to develop orphan drug Trappsol Cyclo
11 May 2015 | By Victoria White
Boyds has joined CTD Holdings’ Clinical Programme Team along with Aptus Clinical and KJC Statistics to develop orphan drug Trappsol Cyclo with Accenture...
